- Home
- CRGY vs RCUS Comparison
CRGY vs RCUS Comparison
Compare CRGY & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRGY | RCUS |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CRGY | RCUS |
|---|---|---|
| Price | $13.68 | $20.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | $14.00 | ★ $29.20 |
| AVG Volume (30 Days) | ★ 9.8M | 1.1M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,579,782,000.00 | $247,000,000.00 |
| Revenue This Year | $27.35 | N/A |
| Revenue Next Year | N/A | $70.88 |
| P/E Ratio | $99.08 | ★ N/A |
| Revenue Growth | ★ 22.14 | N/A |
| 52 Week Low | $6.83 | $6.79 |
| 52 Week High | $13.86 | $26.40 |
Technical Indicators
Market Signals| Indicator | CRGY | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 73.58 | 43.14 |
| Support Level | $8.19 | $18.52 |
| Resistance Level | N/A | $21.55 |
| Average True Range (ATR) | 0.46 | 1.08 |
| MACD | 0.10 | -0.27 |
| Stochastic Oscillator | 86.01 | 3.95 |
Price Performance
Historical ComparisonAbout CRGY Crescent Energy Company
Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The Company's investing and operating activities are focused in Texas and the Rocky Mountain region.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.